Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
3.680
0.00 (0.00%)
Jun 26, 2025, 12:49 PM - Market open
Akebia Therapeutics Employees
Akebia Therapeutics had 181 employees as of December 31, 2024. The number of employees increased by 14 or 8.38% compared to the previous year.
Employees
181
Change (1Y)
14
Growth (1Y)
8.38%
Revenue / Employee
$1,021,597
Profits / Employee
-$250,348
Market Cap
966.50M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AKBA News
- 22 days ago - Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology - GlobeNewsWire
- 23 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025 - GlobeNewsWire
- 4 weeks ago - Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025 - GlobeNewsWire
- 6 weeks ago - Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - GlobeNewsWire
- 7 weeks ago - Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 7 weeks ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire